期刊
VACCINE
卷 39, 期 8, 页码 1195-1200出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2020.12.023
关键词
Malaria; Plasmodium falciparum; Malaria vaccine; Circumsporozoite protein
资金
- NIAID under the Vaccine and Treatment Evaluation Unit (VTEU) [HHSN272201300022I]
- NIH T32 Fellowship Training Program in Vaccinology [T32 AI007524]
- NIAID Malaria Vaccine Production Support Services [AI-N01-054210]
- NIAID [HHSN272201200005I, HHSN272201800009I]
The new full-length rCSP vaccine combined with the GLA-LSQ adjuvant showed a good safety and immunogenicity profile in clinical trials, confirming the immunostimulatory capacity of GLA-LSQ and supporting further steps in clinical product development.
Plasmodium falciparum circumsporozoite protein (CSP) is a major sporozoite surface protein and a key target of pre-erythrocytic malaria subunit vaccines. A full-length recombinant CSP (rCSP) based strategy could be advantageous, as this antigen includes a region critical to sporozoite cell attachment and hepatocyte invasion. The adjuvant Glucopyranosyl Lipid A-liposome Quillaja saponaria 21 (GLA-LSQ) functions as a TLR4 agonist, promotes antigen-specific T(H)1 responses and stimulates cytotoxic T cell production. To date, one study has reported the clinical acceptability of GLA-LSQ. We present interim results of a phase 1 first-in-human dose-escalation clinical trial of full-length rCSP vaccine given with or without GLA-LSQ adjuvant. Participants experienced only mild to moderate related solicited adverse events. The lowest adjuvanted vaccine dose achieved >90-fold rise in geometric mean anti-CSP IgG antibody titer. These favorable safety and immunogenicity results confirm the immunostimulatory capacity of this relatively new adjuvant and support next steps in clinical product development. (C) 2020 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据